[HTML][HTML] New concepts in HIV-1 vaccine development
KE Stephenson, HT D'Couto, DH Barouch - Current opinion in immunology, 2016 - Elsevier
KE Stephenson, HT D'Couto, DH Barouch
Current opinion in immunology, 2016•ElsevierHighlights•Immune correlates of protection are guiding HIV-1 vaccine development.•RV144
follow-on trials aim to generate antibody responses to the V1V2 region of Env.•Immunogens
are being tested to generate polyfunctional Env antibody responses.•Passive transfer of
broadly neutralizing antibodies is being tested in clinical trials.•Replicating viral vectors may
establish a pool of effector memory T-cells.With 2 million people newly infected with HIV-1 in
2014, an effective HIV-1 vaccine remains a major public health priority. HIV-1 vaccine …
follow-on trials aim to generate antibody responses to the V1V2 region of Env.•Immunogens
are being tested to generate polyfunctional Env antibody responses.•Passive transfer of
broadly neutralizing antibodies is being tested in clinical trials.•Replicating viral vectors may
establish a pool of effector memory T-cells.With 2 million people newly infected with HIV-1 in
2014, an effective HIV-1 vaccine remains a major public health priority. HIV-1 vaccine …
Highlights
- Immune correlates of protection are guiding HIV-1 vaccine development.
- RV144 follow-on trials aim to generate antibody responses to the V1V2 region of Env.
- Immunogens are being tested to generate polyfunctional Env antibody responses.
- Passive transfer of broadly neutralizing antibodies is being tested in clinical trials.
- Replicating viral vectors may establish a pool of effector memory T-cells.
With 2 million people newly infected with HIV-1 in 2014, an effective HIV-1 vaccine remains a major public health priority. HIV-1 vaccine efficacy trials in humans, complemented by active and passive immunization studies in non-human primates, have identified several key vaccine-induced immunological responses that may correlate with protection against HIV-1 infection. Potential correlates of protection in these studies include V2-specific, polyfunctional, and broadly neutralizing antibody responses, as well as effector memory T cell responses. Here we review how these correlates of protection are guiding current approaches to HIV-1 vaccine development. These approaches include improvements on the ALVAC-HIV/AIDSVAX B/E vaccine regimen used in the RV144 clinical trial in Thailand, adenovirus serotype 26 vectors with gp140 boosting, intravenous infusions of bNAbs, and replicating viral vectors.
Elsevier